FIELD: pharmacology.
SUBSTANCE: invention relates to the use of oreganol A as a drug with neurotropic activity for the treatment of neurosis and psychosis.
EFFECT: invention makes it possible to increase the effectiveness of the therapeutic effect and exclude the occurrence of side effects.
9 cl, 2 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF PATULYTHRIN AS AN ANTIDEPRESSANT | 2022 |
|
RU2802977C1 |
| USE OF GAULTERIN AS ANTIDEPRESSANT | 2023 |
|
RU2825385C1 |
| USE OF OREGANOL A WITH DIURETIC ACTIVITY | 2022 |
|
RU2802873C1 |
| USE OF QUERCETIN AS A DIURETIC, SALURETIC AND CREATININURETIC AGENT | 2022 |
|
RU2802833C1 |
| USE OF DIHYDROQUERCETIN AS A DIURETIC, SALURETIC AND CREATININURETIC AGENT | 2022 |
|
RU2802874C1 |
| USE OF HYPEROZIDE AS A DIURETIC, SALURETIC AND CREATININURETIC AGENT | 2022 |
|
RU2802832C1 |
| USE OF PATULITRIN AS A DIURETIC | 2022 |
|
RU2807938C1 |
| PHARMACEUTICAL COMPOSITION BASED ON BIS-(N-MONOSUCCINYL-L-SERYL-L-LYSINE) HEXAMETHYLENEDIAMIDE (GSB-106) | 2018 |
|
RU2697254C1 |
| USE OF PINOCEMBRIN AS DIURETIC AND CREATININURETIC AGENT | 2023 |
|
RU2822937C1 |
| USE OF PINOSTROBIN AS DIURETIC AND CREATINURETIC AGENT | 2023 |
|
RU2816948C1 |
